Topic:

R&D

Latest Headlines

Latest Headlines

Alexion bets up to $265M on Blueprint's precision medicine platform

Rare disease magnate Alexion is aligning itself with biotech Blueprint Medicines, borrowing the company's development technology to spotlight new treatments for genetic disorders.

Merck touts a bright future in biosimilars with a stable of would-be blockbusters

Merck may trail the first movers in the coming onslaught of blockbuster biosimilars, but the pharma giant is heralding a crop of late-stage copycat treatments it believes can snag a share of the soon-to-boom market.

Ambitious cancer R&D plans may explain Merck KGaA cutbacks

Anyone looking for some perspective on Merck KGaA's recent R&D cutbacks should check out an interview CFO Marcus Kuhnert gave to CNBC. 

J&J picks the inaugural class for its Bay Area biotech incubator

Johnson & Johnson has opened the doors of its new biotech incubator, bringing in its first 10 resident startups and hoping to galvanize the next generation of life sciences innovators.

Evidence that inhaled oxytocin improves social behavior among autistic patients spurs R&D

Additional evidence that oxytocin increases eye contact among autistic patients adds urgency to the efforts of GlaxoSmithKline, OptiNose and other companies scrambling to develop an inhaled version of the "love hormone."

Skin test could vastly simplify diagnosis of Alzheimer's and Parkinson's

Researchers have discovered that a skin sample taken from behind the ear of patients with either Alzheimer's or Parkinson's disease had levels of the protein tau 7 times higher than those without the condition. Those with Parkinson's showed levels of alpha-synuclein protein that were 8 times higher than those in the control group.

MSK and Atara snag an FDA 'breakthrough' tag for T cell project

Memorial Sloan Kettering Cancer Center picked up the FDA's coveted breakthrough-therapy designation for a promising T cell therapy, working with partner Atara Biotherapeutics to get it on the market for patients with complications tied to bone marrow transplants.

Japanese 3-D bioprinter startup Cyfuse raises $12M in Series B to go global

Cyfuse Biomedical is aiming to take its 3-D bioprinting technology to researchers around the world with its infusion of ¥1.4 billion ($12 million). Its bioprinter can be used to create tissue structures including cartilage and subchondral bone, tubular tissues such as blood vessels, digestive and urinary organs, and miniature livers.

Startup Akili partners with nonprofit Autism Speaks to test video game

Akili Interactive Labs has partnered with the nonprofit Autism Speaks to conduct a clinical trial of its cognitive assessment and personalized treatment video game.

Novartis looks to squelch neuro worries over its would-be cardio blockbuster

Novartis, at work on a cardio drug widely expected to bring in billions of dollars once approved, is working to tamp down concerns that the oral treatment could increase the risk of Alzheimer's disease, adding measures of brain function to an ongoing trial.